u/marta_vanhecke

Which plan type?

Yes, exactly this, and it is the bit that took me 46 weeks to accept.

Strongly agree. Heart rate escalation needs the actual data, not impressions.

external review is the appeal after insurance says no

Which trial arm and what was the n?

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

Strongly agree. Heart rate escalation needs the actual data, not impressions.

This order history matches mine almost exactly. Same vendor, same timeframe, same result.

This is correct. Triple agonism is genuinely different.

nobody should be giving this to anyone without extensive monitoring

Are you quoting phase 2 or is there phase 3 data now?

Batch number? Date? Method? Give us the load-bearing fields.

That is net peptide content, not purity. Different number, different meaning.

The Janoshik and PeptideMeter numbers on the same vial from QST came back 93.7% and 99.3%. Both are right, inter-lab variance is real.

phase 2 numbers are not maintenance numbers, cite the trial

independent test or vendor COA, which is it

did they reship, credit, or ghost you?

Sceptical. If this were true we would see it reflected in the data and we do not.

Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.

say which country and which plan type

Adding to this: appeal is doing more work than the comment implies.

Water content matters more than people think. If a vial is carrying residual moisture, your "10mg" is not 10mg of peptide.